Physician profile
Asma Afzal
NPI 1093795775
$1,655.45
in general payments reported to CMS, 2019-2025
10 companies · $580 in 2025
The $580 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $726 · 2024: $349 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,647 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,646.55 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $924.73 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $145.64 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Exact Sciences Corporation | $130.26 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $109.91 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $70.13 | 2023-2025 | Mounjaro, Zepbound |
| Medtronic, INC. | $64.60 | 2023 | Intellis Adaptivestim |
| Amgen INC. | $58.50 | 2023-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $58.14 | 2023-2024 | Vraylar |
| Idorsia Pharmaceuticals US INC | $52.45 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $41.09 | 2023-2025 | Arexvy, Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Afzal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.